tasimelteon + ethanol

This is a **combination** of tasimelteon, a selective dual melatonin receptor agonist, and ethanol (alcohol). Tasimelteon is approved for the treatment of Non-24-Hour Sleep-Wake Disorder, particularly in totally blind individuals[6]. Tasimelteon acts by activating melatonin MT1 and MT2 receptors in the suprachiasmatic nucleus, thereby regulating circadian rhythms[2][3][6]. Ethanol is not used as an active therapeutic agent in the combination but is studied for its interaction and additive effects with tasimelteon on the central nervous system, particularly regarding psychomotor performance[1][3][4][5]. Combination was studied to assess pharmacokinetic and pharmacodynamic interactions rather than as a marketed therapy.